Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(16/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(16/week)
News
United States
(600/week)
Manufacturing
(427/week)
Energy
(314/week)
Technology
(448/week)
Other Manufacturing
(344/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
GT Biopharma, Inc.
Jan 04, 2021
GT Biopharma (OTCQB: GTBP) Announces Corporate Update Conference Call
Oct 22, 2019
GT Biopharma Announces Solid Tumor Targeting TriKe(TM) Kills Non-small Cell Lung Cancer (NSCLC) Tumor Cells
Oct 03, 2019
GT Biopharma Announces HIV TriKE(TM) Data Demonstrating NK Cell Killing of Patient HIV Infected Cells
Sep 26, 2019
GT Biopharma Announces HIV Trike(TM) Data to be Published
Sep 24, 2019
GT Biopharma Announces the Sale of Its Fixed Dose Combination Tablet (GTB-004) for Myasthenia Gravis (Chronic Autoimmune Disease) to DAS Therapeutics
Sep 12, 2019
GT Biopharma Announces FDA Notification of Commencement of Enrollment in Human GTB-3550 Trike(TM) Phase i/ii Clinical Trial
Jun 10, 2019
GT Biopharma Company Update
May 30, 2019
GT Biopharma GTB-1550 Clinical Development Update
May 29, 2019
GT Biopharma GTB-1550 PHASE I-II Results to be Published in Conjunction With 2019 ASCO Meeting May 31 - June 4 in Chicago
Apr 25, 2019
GT Biopharma (GTBP) to Broadcast Update on TriKE Initiatives for HIV and Oncology at University of Minnesota On May 7th; Dr. Jeff Miller And Dr. Timothy Schacker to Host Event
Apr 24, 2019
GT Biopharma (GTBP) Announces the Elimination of HIV Infected Cells Using its Tri-Specific Killer Engagers (TriKEs) in Preclinical Testing at the University of Minnesota
Apr 08, 2019
GT Biopharma Receives Institutional Review Board Approval to Proceed With in Human FDA Phase 1 Clinical Trial
Jun 11, 2018
GT Biopharma Announces Preliminary Clinical Results From Interim Review of Phase 1/2 Clinical Trial of OXS-1550, its Bi-Specific Antibody Drug Conjugate
Apr 10, 2018
GT Biopharma, Inc. Announces it has Completed Enrollment in Proof-of-concept Clinical Trial for its Novel Treatment for Motion Sickness
Latest News
Apr 26, 2024
Cleveland-Cliffs to Publish Monthly Hot Rolled Coil Spot Price
Apr 26, 2024
Oil States Announces First Quarter 2024 Results
Apr 26, 2024
Phillips 66 Reports 1Q 2024 Financial Results, Highlights Strategic Priorities Progress
Apr 26, 2024
Rockwell Automation to Present at Oppenheimer’s 19th Annual Industrial Growth Conference
Apr 26, 2024
Sensient Technologies Corporation Reports Results for the Quarter Ended March 31, 2024 and Raises Full Year...
Apr 26, 2024
GrafTech Reports First Quarter 2024 Results
Apr 26, 2024
Nextracker and JENNMAR Subsidiary JM Steel Bolster U.S. Supply Chain with New Facility Expansion to Triple...
Apr 26, 2024
Civeo Reports First Quarter 2024 Results
View all News
Agenda
29
October
United Kingdom
Copthorne Tara Hotel, London, UK
International Dismounted Soldier, 29-30 October 2024, Copthorne Tara Hotel, London, UK
Navigating the Evolving Battlespace: Enhancing the Capabilities of the Dismounted Soldier The modern battlefield...
24
September
United Kingdom
Hilton London Syon Park, London, UK
Defence Transformation Conference, 24-26 September 2024, Hilton London Syon Park, London, UK
Returning for its 8th year, Defence Transformation 2024 will feature an updated format that will address all aspects of...
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
View All Events